Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63-MVA CS vs ChAd63-MVA ME-TRAP Malaria Challenge Study
NCT01623557Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2012
- Primary completion
- Nov 2012
- Modality
- Viral Vector Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ChAd63 CS, MVA-CS, ChAd63 ME-TRAP and MVA ME-TRAP in Plasmodium falciparum malaria (3 arms), sponsored by University of Oxford. Primary endpoint: Effectiveness at preventing malaria infection. Started Apr 2012; status: completed.
02
Drugs
ChAd63 CSMVA-CSChAd63 ME-TRAPMVA ME-TRAP
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01623557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01623557.